A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, a Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date8/03/22 → 7/03/27

Keywords

  • Phase 1 and 2 study
  • treatment safety
  • treatment efficacy
  • dose escalation
  • monoclonal antibody
  • metastic cancer

Clinical Trial Phase

  • Phase I
  • Phase II